A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis

NCT01148225 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

424

Enrollment

INDUSTRY

Sponsor class

Conditions

Uveitis

Interventions

DRUG: adalimumab

Sponsor

AbbVie